• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
REN Jie,JIANG Yan,ZOU Sulan,CHEN Rong,HU Nan.Investigation of pharmacokinetics of cyclosporine with NONMEM in type 1 diabetic rat model[J].Journal Of Pharmaceutical Research,2018,37(11):630-633[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 3443times   Download 2711次 QR Code for this article
Scan with your phone!
非线性混合效应模型法计算1型糖尿病大鼠环孢素药代动力学参数
任洁,蒋艳,邹素兰,陈荣,胡楠
Font:Larger+|Default|Smaller-
(常州市第一人民医院药剂科,江苏 常州 213003)
摘要:
目的 研究糖尿病对环孢素(Ciclosporin, CsA)体内药物代谢动力学的影响。方法 大鼠腹腔注射65 mg·kg-1链脲菌素(STZ)建立1型糖尿病大鼠模型。造模5周后通过荧光偏振免疫分析(FPIA)法检测大鼠灌胃环孢素(10 mg·kg-1)后全血中的环孢素浓度,采用非线性混合效应法(Nonlinear mixed effect model, NONMEM)建立药物代谢动力学模型,贝叶斯(Bayes)反馈法获取个体参数并比较。结果 STZ注射1周后,大鼠空腹血糖超过11.1 mmol·L-1,确认1型糖尿病大鼠造模成功。造模5周后,糖尿病大鼠的血糖显著增高。给药后,环孢素在大鼠体内呈现一房室模型,群体典型值及个体间差异(Between Subject Variability, BSV)分别为:CL/F=0.525 L·h-1, BSV=32.1%;V/F=5.18 L, BSV=35.6%; Ka=1.82,BSV= 71.1%。正常组与糖尿病组大鼠CL/F无显著性差异(P>0.05);V/F无显著性差异(P>0.05);Ka有显著性差异(P<0.05) 。结论 1型糖尿病大鼠灌胃环孢素的吸收速率常数显著改变,且存在较大的个体间差异,提示糖尿病状态下会影响环孢素的吸收。
关键词:  糖尿病  大鼠  环孢素  非线性混合效应模型法  药代动力学参数
DOI:10.13506/j.cnki.jpr.2018.11.003
基金项目:国家自然科学基金青年基金(No.81503136)
Investigation of pharmacokinetics of cyclosporine with NONMEM in type 1 diabetic rat model
REN Jie,JIANG Yan,ZOU Sulan,CHEN Rong,HU Nan
(Department of Pharmacy,The First People’s Hospital of Changzhou,Changzhou 213003,China)
Abstract:
Objective To investigate the effect of diabetes on oral pharmacokinetics of cyclosporine A (CsA). Methods Rats with type 1 diabetes were induced by streptozotocin (STZ) with the dose of 65 mg·kg-1 during intraperitoneal administration. Oral pharmacokinetics of CsA (10 mg·kg-1) was compared between diabetic and normal rats on the 35th day after STZ injection. Concentration of CsA in whole blood was measured by a specific monoclonal fluorescence polarization immunoassay (FPIA). Pharmacokinetic analysis was conducted using the nonlinear mixed effects modeling (NONMEM) program. Results The glucose in serum of diabetic rats which were induced as the fasting blood glucose levels exceed 11.1 mM after STZ injection for 1 week was significantly higher than those in normal rats after STZ injection for 35 days. A model with one compartment model had the best predictive performance for the pharmacokinetic (PK) model. The population estimates of CsA were 0.525 L·h-1 for clearance (CL/F), 5.18 L for volume of distribution (V/F) and 1.82 /h for ka. Compared with two groups, there were no difference between group of control (CON) and group of DM for CL/F (P>0.05) and V/F (P>0.05), but with significantly difference for Ka(P<0.05).Conclusion In summary,the oral pharmacokinetics Ka of CsA was significantly different in type 1 diabetic rat model compared to CON,which should be taken into consideration in clinical medication.
Key words:  Type 1 Diabetes  Rats  Cyclosporine  Nonlinear mixed effect model (NONMEM)  Pharmacokinetics
Today's Visits:488    Total Visits:2383203
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.